Daily Current Affairs in English & Hindi

Important current affairs for every date with key points and exam facts — curated for UPSC, SSC, Banking and State PCS aspirants.

Jump to any date
Read current affairs from any day in the archive

Latest headlines

View all

Merchandise exports surge by 20% as India diversifies trade

India's merchandise exports grew by nearly 20% in July 2026, reaching $44.2 billion, despite ongoing turmoil in West Asia. This growth was attributed to market diversification and adaptive trade strategies, including re-routing shipping lines. Exports to West Asia recovered, up almost 9% year-on-year, while exports to China surged by 65% to $2.2 billion. However, the trade deficit widened to $15 billion due to slower growth in services exports (6.4%) compared to services imports (9.5%), indicating a need to boost high-value exports and competitiveness in services.

  • India's merchandise exports grew by 19.6% in July 2026, reaching $44.2 billion, driven by market diversification and adaptive trade strategies.
  • Exports to West Asia recovered significantly, showing an 8.8% increase in July 2026 compared to the previous year, despite earlier contractions.
  • Exports to China saw a substantial surge of 65% in July 2026, reaching $2.2 billion, and a 36% growth over April-July.
Exam Points
  • Merchandise exports in July 2026: $44.2 billion (19.6% growth).
  • Trade deficit in July 2026: $15 billion.
  • Exports to China in July 2026: $2.2 billion (65% growth).
Read more

Why vital chemotherapy drugs in short supply in India

India is facing a critical nationwide shortage of key chemotherapy drugs, cisplatin and carboplatin, due to soaring global platinum raw material costs, West Asia shipping disruptions restricting raw material imports, and domestic price caps. While government hospitals have managed to stabilize supplies, private hospitals are struggling, leading to treatment interruptions for cancer patients. In response, the government, through the NPPA, temporarily raised the ceiling prices of these drugs by 50% to restart domestic manufacturing, highlighting vulnerabilities in India's drug supply chains and pricing framework.

  • India is experiencing a critical shortage of cisplatin and carboplatin, vital chemotherapy drugs, due to multiple factors.
  • The primary causes include a more than doubling of platinum raw material prices, shipping constraints via West Asia, and unviable domestic price caps.
  • The shortage has led to treatment interruptions and delays for cancer patients, particularly in private hospitals, while government hospitals have managed to stabilize supplies.
Exam Points
  • Drugs in shortage: Cisplatin and Carboplatin.
  • NPPA raised price cap by ~50% on June 12.
  • Cisplatin price cap raised from ₹7.26 to ₹10.89 per ml.
Read more

Transparency as the foundation of trust in medicine

The article emphasizes that trust in medicine is built not just on the doctor-patient relationship but also on institutional transparency across regulatory bodies, hospital systems, and clinical care. It highlights the need for publicly accessible regulatory frameworks, clear communication about medical costs and processes, and a culture of "Open Disclosure" when things go wrong. The author notes that India's current regulatory transparency is uneven and suggests that improving user-friendliness of digital portals and formalizing open disclosure can significantly strengthen public faith, reduce mistrust, and protect both patients and healthcare workers.

  • Trust in medicine is fundamentally built upon transparency within regulatory bodies, hospital systems, and clinical care, not solely on individual doctor-patient interactions.
  • Institutional transparency requires accessible regulatory frameworks, clear communication about medical costs and processes, and a culture of "Open Disclosure" for errors.
  • India's current regulatory transparency is uneven, with challenges in accessing doctor credentials and varying levels of clarity in hospital processes.
Exam Points
  • Doctors' Day in India: July 1.
  • Example of regulatory body: Tamil Nadu Medical Council (TNMC).
  • Example of regulatory body: National Medical Commission (NMC).
Read more

Europe's AI rules may become India's opportunity

India is considering standalone AI legislation, coinciding with the EU's AI Act, which will apply from August 2, 2026. The EU Act adopts a risk-based approach, requiring "conformity assessment" for high-risk AI systems and mandating re-assessment for "substantial modifications." This poses a challenge for India's dynamic tech industry, which thrives on responsive adaptation. However, the article argues that this regulatory framework also presents an opportunity for India to build an industry around providing AI compliance services, leveraging its legal and technical professionals, and potentially becoming a participant in the EU's conformity assessment ecosystem through trade agreements.

  • India is contemplating its own AI legislation, aligning with the EU's AI Act which comes into force on August 2, 2026.
  • The EU AI Act employs a risk-based approach, requiring rigorous "conformity assessment" for high-risk AI systems and mandating re-evaluation for any "substantial modification."
  • This regulatory structure presents a challenge for India's tech industry, which often relies on continuous, unplanned improvements to AI systems.
Exam Points
  • EU AI Act entered into force: August 2024.
  • EU AI Act applicable from: August 2, 2026.
  • EU AI Act Article 43: requires "conformity assessment" for high-risk AI systems.
Read more

Browse by date

Browse by topic

Read it. Retain it. Recall it.

Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.

Get it on Google Play